trial

Oxytocin as Adjunctive Treatment of Schizophrenia

NCTId NCT01568528
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 39 (actual)
Sponsored by Emory University
Primary completion 2017-03-15
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
39 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2013-03
Primary completion
2017-03-15
Eligibility
MALE · 18 Years · 65 Years

Interventions & indications

Drugs
Oxytocin

Sponsors

Emory UniversityLead Sponsor
Atlanta VA Medical CenterCollaborator

Investigators

1
Erica J. Duncan, MDPrincipal Investigator

Sites

1 total
Decatur, United States

Linked catalysts

1
Oxytocin as Adjunctive Treatment of Schizophrenia — primary completion2017-03-15

Facts & assertions

4 sourced
Enrollment
39
Phase
PHASE2
Primary Completion Date
2017-03-15
Status
COMPLETED
relationships
The graph out of here
drug
Oxytocin
drug
lead_sponsor
Emory University
company
collaborator
Atlanta VA Medical Center
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Erica J. Duncan, MD
person